Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Immune checkpoint therapy—current perspectives and future directions
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …
patients and conferred durable clinical benefits, including cure in a subset of patients …
LAG-3 as the third checkpoint inhibitor
Abstract Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly
expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more …
expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more …
T cell exhaustion
A Baessler, DAA Vignali - Annual review of immunology, 2024 - annualreviews.org
T cell responses must be balanced to ensure adequate protection against malignant
transformation and an array of pathogens while also limiting damage to healthy cells and …
transformation and an array of pathogens while also limiting damage to healthy cells and …
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
Summary LAG-3, TIM-3, and TIGIT comprise the next generation of immune checkpoint
receptors being harnessed in the clinic. Although initially studied for their roles in restraining …
receptors being harnessed in the clinic. Although initially studied for their roles in restraining …
LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical
challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined …
challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined …
Xanthene, cyanine, oxazine and BODIPY: the four pillars of the fluorophore empire for super-resolution bioimaging
In the realm of biological research, the invention of super-resolution microscopy (SRM) has
enabled the visualization of ultrafine sub-cellular structures and their functions in live cells at …
enabled the visualization of ultrafine sub-cellular structures and their functions in live cells at …
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
Summary Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective
for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced …
for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced …
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
N Yin, X Li, X Zhang, S Xue, Y Cao… - … and Targeted Therapy, 2024 - nature.com
Immunotherapy represented by anti-PD-(L) 1 and anti-CTLA-4 inhibitors has revolutionized
cancer treatment, but challenges related to resistance and toxicity still remain. Due to the …
cancer treatment, but challenges related to resistance and toxicity still remain. Due to the …
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function
Lymphocyte activation gene-3 (LAG-3) is an inhibitory receptor expressed on activated T
cells and an emerging immunotherapy target. Domain 1 (D1) of LAG-3, which has been …
cells and an emerging immunotherapy target. Domain 1 (D1) of LAG-3, which has been …
Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein
Pathologic α-synuclein (α-syn) spreads from cell-to-cell, in part, through binding to the
lymphocyte-activation gene 3 (Lag3). Here we report that amyloid β precursor-like protein 1 …
lymphocyte-activation gene 3 (Lag3). Here we report that amyloid β precursor-like protein 1 …